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INTRODUCTION
Muscle  weakness  is  associated  with  a  number  of  different  electrolyte 
disorders  including  hyperkalemia,  hypercalcemia  and  hypo  or  hyper 
magnesemia.However,  hypokalemia  emerges  as  the  most  prevalent  cause  of 
periodic paralysis
Periodic paralysis includes a range of unique disorders and syndromes of 
varying genetic origin and symptomatology. The discovery of the adult human 
skeletal muscle voltage dependant channel had led to the discovery of specific 
gene  lesions  in  different  portion of  the  channel  structure that  are  associated 
primarily with the potassium sensitive periodic paralysis. 
Autosomal dominant mutations in the CACNAIS gene4 encoding the  α1 
subunit  of L-type calcium channels are the  most  common genetic cause of 
hypokalemic periodic paralysis. Whereas type II hypokalemic periodic paralysis 
is  caused  by  mutations  in  the  SCN4A  gene2 encoding  the  skeletal  sodium 
channel.
Clinical  and laboratory investigations  are  in progress  to  determine  the 
relationship  between  the  phenotype  and  the  genotype  in  families  having 
different  form of  muscle  diseases  with  known genetic  defects  affecting  the 
skeletal muscle sodium channel.
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The case study described in detail in the subsequent pages will give some 
knowledge about preventing acute attacks of hypokalemic periodic paralysis, 
diagnosing it at its onset and to  treat it promptly, so that injury to the muscle 
can be limited  and the patient saved.
This   study  will  also  give  some  information  about  myopathic  forms, 
which usually presents with progressive muscle weakness without any history 
of episodic paralysis that can be diagnosed by muscle biopsy.
This will also highlight the importance of family history and past history 
of similar weakness as these patients and  the family members who carry the 
mutations are  at slightly increased risk of developing malignant hyperthermia 
in the peri-operative time. 
3REVIEW OF LITERATURE
HISTORICAL BACKGROUND:
Hypokalemic  Periodic  paralysis  is  the  best  known  form  of  periodic 
paralysis.   The  history  of  this  disease  is  difficult  to  trace,  but  the  first 
unmistakable account was probably that of  Hartwig in 1874, followed by the 
accounts of Westphal in 1885 and Oppenheim in 1891. Goldflam in 1895 first 
called  attention  to  the  remarkable  vacuolization  of  the  muscle  fibers  that  is 
characteristic of the process.
In 1937, Aitken and associates described the occurrence of low serum 
potassium  during  attacks  of  paralysis  and  reversal  of  the  paralysis  by 
administration of potassium, thus setting the stage for subsequent differentiation 
of the hyperkalemic forms of periodic paralysis. 
Talbott’s monograph serves as the best historical review of the subject, 
and includes all cases that have been reported prior to 1941.  The most recent 
reviews by Layzer and by Lehmann, Horn and Engel  and their associates bring 
the subject largely up to date.
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The  disease  has  been  observed  in  all  parts  of  the  world  .   Periodic 
paralysis can be broadly classified as two types. 
1. Primary
2. Secondary
Primary Periodic Paralysis (also known as channelopathies)20
  Here,  the  diagnosis  is  based  on history  and confirmed  by appropriate 
evaluation of electrolytes.
It is classified as:
1. Hypokalemic periodic paralysis
2. Hyperkalemic periodic paralysis
3. Anderson’s disease 
4. Paramyotonia congenita 
 The differences between the various form of channelopathies are given 
in table-I. 
Differential diagnosis for secondary hypokalemic periodic paralysis6
1. Thyrotoxic periodic paralysis
2. Periodic Paralysis secondary to renal potassium wastage
3. Periodic Paralysis secondary to gastrointestinal loss
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Hypokalemia secondary to gastrointestinal loss:
1. Laxative abuse
2. severe or chronic diarrhea 
3. Villous adenoma
4. congenital chloride losing diarrhea
Hypokalemia secondary to Renal loss:
 1.   Hypertension. alkaline urine, metabolic alkalosis:
1. Primary hyperaldosteronism
2. Liquorice ingestion
3. Excessive diuretic therapy
4. Excessive mineralocorticoid  therapy for Addison’s disease
   2. Normotension , alkaline urine, metabolic alkalosis
      Hyperplasia   of  the  juxta  glomerular  apparatus  with 
hyperaldosteronism 
   3.  Alkaline Urine, metabolic acidosis:
Renal Tubular acidosis
1. Primary
2. Secondary
   4. Acidic Urine , Metabolic acidosis:
Chronic ammonium chloride ingestion
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Recovery phase of diabetic ketoacidosis
Recovery phase of acute tubular necrosis
   5.  Antibiotic Therapy:
Amphotericin B
Gentamycin
Carbenicillin
Ticarcillin
others
Pharmacological agents
1. Beta Agonists
2. Insulin
3. Barium
4. Epinephrine and norepinephrine
5. Glucocorticoids
6. Thiazide
TABLE-I
THE CHANNELOPATHIES
Channel 
affected Sodium Sodium Calcium Potassium
Disease Hyperkalemic 
Periodic 
Paralysis 
Paramyotonia 
Congenita 
Hypokalemic 
Periodic 
Paralysis 
Anderson 
disease 
Inheritence Dominant Dominant Dominant Dominant 
Gene SCN4A SCN4A DHP receptor KCNJ2
Channel 
Protein
Alphasubunit Alpha 
subunit
Dihydropuridine 
receptor 
Inward 
rectifying K’ 
Channel 
Myotonia 
(electrical)
+/- ++ - -
Myotonia
(Clinical)
+/- - - -
Paramyotonia 
(Clinical)
+/- +++ - -
Episodic 
Paralysis 
+++ +/- +++ +
Onset First decade Paramyotonia 
at Birth
Latechildhood 
to third decade
childhood 
Precipitating 
factors 
Increases 
with exercise 
- +++ - +
Appears after 
exercise 
++ - ++ -
Fasting + - - -
Carbohydrate 
load 
- - + -
Potassium 
load
++ +/- - -
THE CHANNELOPATHIES
Cold + +++ + -
Pregnancy ++ - + ?
Warm-up 
phenomenon
+ - + -
involvement 
of cranial 
muscles 
+ ++ - ++
muscle 
hypertrophy 
- - - -
permanent 
myopathy 
++ - ++ +
Serum ck 
during attack
Increased Increased 5 
to 10 times 
Normal to 
Slightly 
increased 
Normal 
Serum K 
during attack 
Increased Normal Decreased High, low or 
normal 
Serum K 
between 
attacks 
Normal Normal Normal Normal
Significant 
myopathy
++ - ++ Tubular 
aggregates
Treatment during attack 
glucose and 
calcium for 
prevention – 
acetazolamide 
CHO, Low K 
diet 
Mexiletine if 
needed  for 
myotonia
KCL during and 
acetazolamide 
between attacks
acetazolamide
K - Potassium
    CHO - carbohydrate
  + mild
  ++ moderate
  +++ severe
7PATHOPHYSIOLOGICAL MECHANISM
The  pathophysiology  of  hypokalemic  periodic  paralysis  is  not  clear. 
Electrophysiologic  studies  performed  in  vitro  on  muscle  fibers  from 
hypokalemic  patients  revealed  alterations  in  membrane  excitability.  These 
observations  suggested  that  ion  channels   might  be  implicated  in  the 
pathophysiology of the disease. 
Given the electrophysiologic data, the first strategy chosen was to test for 
linkage  to  known  ion  channel  genes.   The   initial  linkage  studies  were 
conducted  with  three  families  of   Portuguese,  German  and  French  descent 
Positive iod scores were observed for markers localised on chromosome  1q31-
32  establishing  the  hypokalemic  periodic  paralysis   1  locus.   The   calcium 
channel1 α1  subunit CACNLIA3 also called dihydropyridine  receptor ( DHP 
receptor) was mapped to the same 5 – c M interval as the hypokalemic periodic 
paralysis   1  locus.   Three mutations  were subsequently  found in the coding 
sequence  of CACNLIA3, establishing it as the  hypokalemic periodic paralysis 
gene .
One mutation replaces a positively charged arginine by a weakly positive 
histidine in position 528 in segment S4 of domain II.  The other two replace an 
arginine with either a histidine or a glycine in position 1239 segment S4 of 
domain IV .  The ARG 528 His and Arg 1239 His  mutations were present in 
8approximately  90% of  the  hypokalemic  periodic  paralysis  families,  each  of 
them found in approximately 50% of cases.  The phenotype  was identical in 
terms  of  attacks  and  of  development  of  a  vacuolar  myopathy.  Incomplete 
penetrance  was  observed  only  with  the  ARG  528  HIS  mutation. 
Characterization of the haplotypes segregating with the mutations demonstrated 
that the predominance of these two mutations was due not to a founder effect 
but to recurrence mutations.  
Till date 7 mutations have been described in α1  subunit of  CACNLIA3 
thus  accounting  for  approximately  55-70%  of  all  hypokalemic  periodic 
paralysis. 
These includes
ARG1239HIS
ARG528 HIS
ARG528GLY
ARG1239GLY
ARG1086CYS
ARG1086HIS
Other mutations involve sodium – channel2  voltage gated,  type IV  α 
subunit.   The  gene  has  been  mapped  to  chromosome   17q23.1-q25.3.  This 
account for approximately 8 – 10% of hypokalemic periodic paralysis type II 
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Five  mutations described to date  that includes
ARG669HIS
ARG672HIS
ARG672GLY
ARG672SER
PRO1158SER
Some evidence exits that patients with this sodium channel mutation are 
phenotypically different form the  more common CACNAIS  form.  These types 
of  mutation  are  associated  by  the  presence  of  myalgias  following  paralytic 
attacks;  tubular  aggregates  instead  of  vacuoles  in  the  muscle  biopsy  and 
worsening of symptoms by acetazolamide  (sternbery et al. 2001)  
CLINICAL FEATURES
Hypokalemic periodic paralysis is inherited as an autosomal dominant7 
disorder in 2/3rd of cases and sporadic in 1/3rd 
 Males are most commonly affected with male to female  ratio 
of 3 or 4:1)  
 Females have a low penetrance
 Attacks characterically begin in adolescence
 Onset after 30 years is rare 
10
 Attack frequency varies from days to years.
 Duration of single attack lasts from hours if mild to days it severe
 The  frequency of attack tend to lessen with advancing age 
 Typical attack comes on during the second half of the night or the 
early morning  hours after a day of unusually strenuous exercise or a 
meal rich in carbohydrates. 
Hypokalemic periodic paralysis   is characterized  by two forms :
1. Paralytic form
2. Myopathic form:
PARALYTIC FORM:
The weakness may be proceeded by certain prodromes such as excessive 
hunger, thirst, dry mouth, palpitations, sweating, diarrhea,  vomiting and a sense 
of  weariness  or   fatigue.  Usually  the patient  awakens to discover  a  mild  or 
severe weakness of the limbs. However diurnal attacks also occur, especially 
after a nap following a large meal.  The  attack  evolves over minutes to several  
hours, at its peak it may render the patient so helpless as to be unable to call for 
assistance. 
The distribution of paralysis varies. Limbs are affected earlier and  often 
more  severely than  truncal muscle and proximal muscles are possibly more 
susceptible than distal ones. The legs are often weakened before the arms but 
exceptionally the order is reversed.  The muscle most likely to escape are those 
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of  eyes,  face,  tongue,  pharynx,  larynx,  diaphragm,  and  sphincters,  but   on 
occasion even these may be involved.  when the attack is at its peak  tendon 
reflexes are reduced or  abolished and cutaneous reflexes may also disappear. 
Sensation is preserved.  As the attack subsides strength generally returns first to 
the muscle that were last to be affected.
Headche, exhaustion. diuresis and occasionally diarrhea may follow the 
attack. Myotonia is not seen: indeed clinical or EMG evidence of  myotonia 
essentially excludes the diagnosis of hypokalemic Periodic  paralysis.  Rarely, 
death  may occur from respiratory paralysis or derangement of the conducting 
system of the heart.
The atypical forms of presentation include:
1. Weakness of one limb or certain group of muscle 
2. Bibrachial palsy
3. Transient weakness during accustomed activities.
MYOPATHIC FORM:
This  form develops  in  approximately  25% of  affected  individuals  and 
results in a progressive fixed muscle weakness that begins at extremely variable 
ages  as  exercise  intolerance  predominantly  in  the  lower  limbs.   It  occurs 
independent  of  paralytic  symptoms  and  may  be  the  sole  manifestations  of 
hypokalemic periodic paralysis.  
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Recognized trigger for hypokalemic periodic paralysis18
1. High carbohydrate diet
2. Large meals
3. salt
4. Sleep after unaccustomed exercise.
5.  Medications eg: diuretics, insulin
The  resting membrane  potential of the skeletal muscle has been altered 
in these patients and when potassium level falls down the RMP goes to   -50MV 
at which the muscles becomes inexcitable.
DIFFERENTIAL DIAGNOSIS:
The differentiation between different type of periodic paralysis are given 
in the table.
Periodic paralysis can be readily distinguished from 
 Guillian – Barre syndrome
Weakness  is  usually  of  the  ascending  type,  antecedent  infective 
episode  might  be  present.  Potassium levels  may  not  be  low.  CSF 
analysis will be supportive.
 Poliomyelitis
More asymmetrical, antecedent gastrointestinal manifestations might 
be present.
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 Cataplexy:
Which lasts only for few seconds or minutes and is precipitated by 
emotion.
  Sleep Paralysis.
The episodes are very brief
 Myasthenia gravis
Ocular involvement more common
 Hysterical Paralysis.
DIAGNOSIS:
Established  by  demonstration  of  low or  low normal  serum potassium 
during  a  typical  paralytic  attack  and  by  excluding  secondary  causes  of 
hypokalemia.
An important  limitation  is  that  the use of serum potassium to give a 
reliable index of true mild hypokalemia is associated with inaccuracies in the 
measurement of serum potassium.  Potassium may be unintentionally released 
from  the  intracellular  compartments  during  the  collection  of  venous  blood 
samples, released from platelets, as the blood coagulates prior to centrifugation 
of the sample or due to mild hemolysis.
These factors can elevate serum potassium by .5 mmol/l or more
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Also, true potassium deficiency can be masked by acidosis, renal failure, 
or tissue destruction and liberation of potassium. 
Electrocardiogram during attacks may show features characteristic of 
hypokalemia27
These includes
1. Flattening or inversion of ‘T’ waves
2. Prominence of ‘U’ waves
3. ST segment depression
4. Wide QRS complexes
5. Prolonged QT interval  
6. Prolonged PR interval
7. Atrial and ventricular extrasystole.
Electromyogram:
The muscular weakness in this disease is associated with  decrease in the 
amplitude, and eventual loss, of muscle action potentials and there is failure  of 
excitation even by supramaximal stimulation of peripheral nerve or by strong 
voluntary effort.  A decline in strength precedes loss of motor unit potentials 
and the failure of propagation of action potentials over the surface of fiber.  The 
polarization potentials of muscle fibers measured by intracellular recordings are 
initially normal despite the failure of impulse   propagation by the sarcolemma. 
One would expect the muscle fiber to be hyperpolarized as K moves into it , 
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 but it actually becomes depolarized.  Rudel and associates attribute the latter 
change to an increased Na conductance.
Histopathological alteration in  hypokalemic periodic paralysis9
The histopathological hallmark of the syndrome is a vacuolar myopathy, 
(Goldflam 1895).  This can be seen in either  primary or secondary periodic 
paralysis, but more often in the former than in the later.  The vacuolation is 
more  consistently   associated  with the permanent  myopathy which develops 
after repeated attacks  than with acute paralysis (Klein et al 1960, Mc Ardle 
1963  Samaha  1965,  Resnick  &  Engel  1967).   The   vacuoles  are  typically 
centrally located in the muscle fibers  and  usually one vacuole but at times 
several appear in a fiber in a single plane of sectioning.  Some vacuoles are 
limited by a delicate membrane.  Some  are loculated, and some contain finely 
granular material staining positively for glycogen. 
Electron microscopic  studies  have  shown that  the  vacuoles  arise  as  a 
result of proliferation and degeneration of membranous organelles within the 
sacrcoplasmic reticulum and transverse tubules. 
Malignant hyperthermia (MH)5 
It  has  been  proven  to  allelic  to  hypokalemic  periodic  paralysis.   All 
hypokalemic periodic paralysis patients must be considered at greatly increased 
risk to this life  threatening complication of surgery.   A persistently  elevated 
CK Could be a hint to Malignant hyperthermia predisposition
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PROVOCATIVE TESTING IN PATIENTS WITH SUSPICION 
OR HAVING SUSPECTTED PERIODIC  PARALYSIS.
INITIAL THERAPY:
This  test  follows an  overnight  fast,  Oral  glucose   1-5  gm/kg  is 
given over three minutes, (maximum of 100 gms)
Monitoring
(with patient at rest)
Free  flowing  arterialized   blood  to  be   obtained 
baseline, every 30 mins upto 3 hours for potassium, 
sodium,  chloride,  co2   glucose,  then  every  60 
minutes for 5 hours.
Strength of the muscle to be assessed at 30 minutes 
interval  in  4  to  6  muscles  based  on muscle  group 
involved during an attack.
ECG to be checked every 30 minutes or continuous 
monitoring is used  if available.
 
Comment
The nadir in serum potassium after oral glucose usually coincides with or 
followed by the peak rise in serum glucose.  Potassium levels in normally after
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 oral glucose loading typically do not fall below 3.5 mmol /L .  If weakness 
occurs, then treat as hypokalemic periodic paralysis.
If  no  weakness  or  adverse  effects  and  if  no  medical  contraindication 
following the initial test, intravenous glucose with insulin can be given.
Following an  overnight  fast,  infuse  intravenously  a  glucose  load of  3 
gms/d (max 200 gm) in water at a continuous rate over 1 hour. A bolus    IV 
insulin is given (.1unit/kg ) 30 minutes after initiation of glucose infusion. 
 Monitoring
(with patient at rest)
Free  flowing  arterialized   blood  to  be   obtained 
baseline, every 30 mins upto 3 hours for potassium, 
sodium,  chloride,  co2   glucose,  then  every  60 
minutes for 5 hours.
Strength of the muscle to be assessed at 30 minutes 
interval  in  4  to  6  muscles  based  on muscle  group 
involved during an attack.
ECG to be checked every 15 minutes or continuous 
monitoring is used  if available.
Caution:   Intravenous  loading  tests  should  not  be  done  in   patients  with 
significant  renal, cardiac or hepatic  disease or in diabetics.  It should be done 
after admission in hospital.
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         Specialized provocative hormone infusion tests include
 Euglycemic insulin infusion over two hours started initially at 
insulin dose of 20mu/m2/min
 Intrabrachial arterial infusion of epinephrine
Comment: 
 These  tests  have  the  advantage  of  producing  a  more  reproducible 
controlled fall in circulating potassium for either the whole body (euglycemic 
insulin  infusion)  or  for  the  forearm  tissues  (eg:  intra  brachial  epinephrine 
infusion. 
BICYCLE TESTING FOR PERIODIC PARALYSIS10
            Bicycle Ergometry Testing- 30 minutes test
1. Patient is tested in early afternoon or late morning. Breakfast is allowed 
but no strenuous  exercise before the test. Each patient lies supine for 
15-30  minutes  with  monitoring  of  baseline  ECG  and  indwelling 
intravenous catherter is placed,  for collection of free flowing samples.
Exercise load in men 100 watts
For women 60 watts.
Blood samples 5,10 minutes before the test
3,6,10,20  and 30 minutes during the test 
3 and 10 minutes after the test
Pedal speed 60 r.p.m. ECG  is monitored through out the tests.
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MOLECULAR GENETIC TESTING:
This identifies disease causing  mutations in CACNAIS or SCN4A in 
80% of individuals meeting clinical diagnostic criteria.
TREATMENT7
Acute paralysis  improves following administration of potassium salts.
Oral  Kcl  0.2-0.4  mmol/kg  should  be  given  to  patients  with  severe 
weakness repeated at 30 to 60 mins interval depending on the response of ECG 
serum potassium and muscle strength.
When  patient  is  not  able  to  swallow  or  when  there  is  vomiting 
intravenous therapy may be necessary.
Small repeated bolus therapy of KCL (.1mmol/kg) may be administered 
over 5-10 mins with careful monitoring of heart.
PREVENTION OF ATTACK:
Diet has not received the same attention in the treatment of hypokalemic 
periodic  paralysis  .   Increased attention to  diet  is  highly justified  due to  its 
potential for decreasing the frequency of paralytic attacks,  the possibility of 
preventing  or  slowing  permanent   muscle  weakness  and  reduced  drug 
requirements in some individuals.  Dietary fat may prove to be an essential key 
to dietary modulation of these disorders.
With all the negative emphasis on fat and cholesterol consumption often 
one  forgets the fact that dietary fat is essential in  maintaining health.  One 
important characteristic of dietary fat that is often overlooked is its role in
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 slowing stomach emptying.  Fat in a meal decreases the rate at which other 
food  components  are  moved  from  the  stomach  to  the  small  intestine  thus 
decreasing the opportunity for a meal to dump its load of carbohydrates into the 
blood all at once.
Simple sugar and even carbohydrates with out the inhibition of fat are 
rapidly  digested  and  absorbed.  Carbohydrates  are  the  primary  stimulus  for 
insulin secretion and the products of protein digestion  also stimulate the release 
of insulin into the  circulation.
Insulin balance is an important consideration in energy metabolism and in 
the  dietary  control  of  channelopathies  like  hypokalemic  periodic  paralysis. 
Carbohydrate  loading  is  a  well   established  trigger  for  paralytic  attack  in 
periodic paralysis and  research has demonstrated  a connection between ATP 
sensitive  potassium  channels  in  the  pathogenesis  of  hypokalemic  periodic 
paralysis.
The other dietary measures include low-sodium diet (160 meq/day) and 
avoidance of large meals.
 The patient should also avoid exposure to cold as this also reduce the 
frequency of attacks.
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Pharmacotherapy for prevention of attacks
  Prophylactic admistration of potassium salts 5 to 10gms of oral 
KCL in an unsweetened aqueous solution prevents attacks in many 
patients, and this can be maintained indefinitely  
 Acetazolamide (125 – 1000 mg/day) usually abolishes attacks.
 In occasional  patients  attacks may be not  respond to or  may be 
worsened by acetazolamide.
 Dichlorphenamide 50 - 1000 mg per day may also be useful 
 Spiranolactone 25-1000 mg/day  may also prevent attacks
 Triameterene 25 -100 mg/day may be tried.
Acetazolamide  can  produce  mild  metabolic  acidosis  which  perhaps 
influences the potassium shifts that occur in this disorder.
Side effects of Acetazolamide:
 Tingling in the digits
 Tendency for formation of renal stones 
 Hypersensitivity  reactions
For   the  late  progressive  polymyopathy.  Dalakas  and  Engle  report 
successful  restoration  of  strength  by  the  long  term  administration  of  the 
carbonic  anhydrase   inhibitor  dichlorphenamide.  Regular  exercise  (  not  too 
strenuous) to keep the patient fit is desirable.
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GENETIC COUNSELLING:
Hypokalemic  Periodic  Paralysis  is  inherited  as  autosomal  dominant 
disorder.   Most  individuals  diagnosed  with  hypokalemic  periodic  paralysis 
have an affected  parent.   The Proportion of  cases  caused by a  denova gene 
mutation is unknown.  Offspring of a proband have a 50%  risk of inheriting the 
mutation.   Penetrance is about 90% in males and may be as low as 50% in 
females depending on the causative mutation.  Prenatal testing is possible if the 
disease  causing   mutation  has  been  identified   in  the  Prohand,  however, 
requests  for  prenatal  testing  for  conditions  such  as  hypokalemic  periodic 
paralysis   that  don’t  affect  the  intellect  and  have  some  treatment  is  not 
advisable.   
PRE OR POST OPERATIVE PARALYSIS
Because  of  the  risk  of  paralysis   preceding   or  following  anesthesia 
precautions should be taken during administration of anesthesia to individuals 
with hypokalemic periodic paralysis.  These patients  should be considered as 
susceptible  to  malignant  hyperthermia  and  managed  with  non  –  triggering 
anesthetic technique.
General  guidelines  for   perioperative   care  include  close  control  of 
plasma potassium  concentration,   avoidance of  large glucose and salt  loads 
carbohydrate poor diets, maintenance of body temperature  and acid base
24
 balance and careful  use of neuromuscular  blocking agents with continuous 
monitoring of neuromuscular function (Hofer et al 2001)
TESTING OF RELATIVES AT RISK:
When a disease causing mutation is identified in a proband, molecular 
genetic testing of at risk asymptomatic family members is appropriate because 
of the risk of un-expected acute paralysis and / or malignant  hyperthermia.
When the results of presymptomatic testing are not known, the at risk 
family members must be considered at risk for complications and precautions 
must be taken, particular in the administration of anesthesia and avoidance of 
risk factors.
         
 
AIM OF THE STUDY
To evaluate cases of hypokalemic periodic paralysis with reference to the 
clinical  presentation,  mode  of  diagnosis,  various  methods  of  treatment  and 
outcome  of  the  different  modalities  of  therapy.   To  find  out  the  ways  of 
preventing acute attacks, early diagnosis of attacks and when they occur to treat 
them effectively. To analyse the age incidence and also gender prevalence.
MATERIALS AND METHODS
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THE STUDY
The study is conducted to evaluate the cases of hypokalemic periodic 
paralysis with reference to the clinical presentation, laboratory parameters, 
treatment and outcome.
Settings
This study is conducted in the tertiary care centre, Government general 
Hospital, Chennai , Medical wards.
Type of study
Prospective
No of cases
40
Period of study
From July 2004 to July 2006
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METHODS AND MATERIALS
Cases admitted in the medical wards with history of flaccid weakness of 
limbs with low serum potassium or electrocardiographic changes suggestive of 
hypokalemia were included in this study.
Also cases referred from other hospitals for evaluation of hypokalemic 
paralysis to find out secondary causes of hypokalemia. 
After admission, a thorough clinical examination of the patient was done 
after eliciting detailed history and blood was sent for biochemical analysis such 
as blood urea, sugar, serum creatinine, serum electrolytes including sodium and 
potassium.
Electrocardiogram was taken simultaneously. Treatment was initiated 
soon after admission.
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INCLUSION CRITERIA
Existence of one of the following:
1. Observation of the paralytic attack by a physician or history typical of 
paralytic attack.  Hypokalemia during the attack was often observed 
but not a prerequisite. 
2. Progressive muscle weakness  plus first degree relatives with 
hypokalemic periodic paralysis. 
3. Characteristic histological findings in muscle biopsy. 
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EXCLUSION CRITERIA
1. Patient with history of systemic  disorders eg: Diabetes  mellitus, chronic 
kidney  disease etc.
2. Patients with history of vomiting, diarrhea.
3. Patients on drugs such as steroids, insulin, diuretics, salbutamol, laxative 
etc,  
4. Abnormal thyroid function test.
5. Abnormal arterial blood gas analysis.
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PARAMETERS CONSIDERED FOR ANALYSIS WERE
1. Age 
2. Sex
3. Past history of similar episode / episodes
4. Family history of similar episodes
5. Precipitating factor if any.
6. Serum potassium level on admission 
7. Electrocardiographic changes
8. Treatment 
9. Outcome
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CLINICAL PROFILE OF HYPOKALEMIC 
PERIODIC PARALYSIS
Name          Age    Sex     IP No.
DOA DOD.
CLINICAL CONTRIBUTORS 
Mode of onset of weakness:
whether paraplegia or quadriplegia :
Ascending / Descending paralysis:
Time of onset of weakness:
Symmetric involvement :
Associated cranial nerve involvement:
Sensory system involvement:
Symptoms  of autonomic system involvement :  
Respiratory muscle dysfunction : 
Precipitating  factors: 
Prodromal symptoms:
History  of  diarrhea , vomiting:
History of drug intake:
History of Diabetes, kidney disease:
History of  thyroid disease:
                Past history of similar episodes:
Number of episodes:
onset of first episodes:
Family history of similar episode:
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CLINICAL EXAMINATION:
Whether Paraparesis / plegia:
Quadriparesis / plegia:
Cranial nerve involvement:
Involvement of neck  muscle:
Reflexes : 
Single breath count:                   
Evidence of myotonia : 
LAB DATA
HB%
TC
DC
ESR
Renal function test.
Blood sugar
Urea
Sr. creatinine
     electrolytes
ABG
Urine analysis – Sodium 
                 Potassium
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ECG in all leads
CXR PA view 
Echocardiogram
USG - Abdomen
Thyroid function test
Serum CPK
THERAPEUTIC CONTRIBUTORS:
Pottasium supplementation
- Oral 
- Intravenous
- Others
Recovery time.
Mortality
FINDINGS
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AGE FREQUENCY
AGE FREQUENCY PERCENTAGE
≤  20Yrs 8 20%
21 - 30Yrs 25 62.5%
31-40 Yrs 7 17.5%
TOTAL 40 100%
Around 60% cases were in their 3rd decades 20% of cases were in their 2nd 
decade
GENDER FREQUENCY
GENDER FREQUENCY PERCENTAGE
MALE 30 75%
FEMALE 10 25%
TOTAL 40 100%
Ratio :
             M  :  F
             3   : 1
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PAST HISTORY FREQUENCY PERCENTAGE
Nil 24 60%
1 time 8 20%
2 times 4 10%
3 times 2 5%
4times 2 5%
TOTAL 40 100%
 About 40% of the cases were found to have suffered similar attacks in the past.
FAMILY HISTORY
FAMILY HISTORY FREQUENCY PERCENTAGE
Present 15 37.5%
Absent 25 62.5%
TOTAL 40 100%
About 37.5% of the total number of patients had 
first degree relatives with similar problem.
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PRECIPITATING FACTOR
FREQUENCY PERCENTAGE
Carbohydrate diet+Sleep 8 20
Sleep - -
Exercise - -
Exercise+Sleep 2 5
Nil 30 75
TOTAL 40 100%
Good carbohydrate diet followed by sleep was found  to be the culprit in many 
patients.
CLINICAL 
FEATURES FREQUENCY PERCENTAGE
Quadriparesis / Plegia 32 80%
Paraparesis /plegia 8 20%
TOTAL 40 100%
About 80% of the patients had presented with Quadriparesis / plegia
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POTASSIUM LEVEL 
IN SERUM meq/L FREQUENCY PERCENTAGE
1.2 4 10%
2.1-3.0 22 55%
3.1-3.5 9 22.5%
3.6-4.0 4 10%
>4 1 2.5%
TOTAL 40 100%
Maximum number of  patients had serum potassium  levels between 2-3 meq/L
ECG FREQUENCY PERCENTAGE
Normal 8 20%
Abnormal 32 80%
TOTAL 40 100%
8 Patients had normal ECG despite of weakness.
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TREATMENT FREQUENCY PERCENTAGE
Oral KCL alone 32 80%
Oral +IV Pot chlor 6 15%
Oral KCL + 
acetazolamide 2 5%
TOTAL 40 100%
Even though different modalities of treatment used almost 80% of patients had 
been treated with Oral  potassium chloride alone.
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RELEVANCE OF CLINICAL MANIFESTATIONS 
WITH POTASSIUM VALUES
CLINICAL SERUM POTASSIUM IN meq/L TOTAL
1.2 2.1to 3.0 3.1 to 
3.5
3.6to 
4.0
>4
Quadriparesis 37.5%
17
42.5%
9
22.5%
2
5%
1
2.5%
32
80%
Paraparesis 12.5%
5
12.5% -
2
5% -
8%
20%
TOTAL 410%
22
55%
9
22.5%
4
10%
1
2.5%
40
100%
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RELEVANCE OF POTASSIUM  VALUES AND ECG.
ECG
SERUM POTASSIUM IN meq/L 
TOTAL1.2 2.1to 
3.0
3.1 to 
3.5
3.6to 
4.0
>4
Normal 12.5%
4
10% -
2
5%
1
2.5%
8
20%
Abnormal 37.5%
18
45%
9
22.5%
2
5% -
32
80%
TOTAL 410%
22
55%
9
22.5%
4
10%
1
2.5%
40
100%
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AGE BY GENDER
AGE IN YEARS MALE FEMALE TOTAL
≤  20Yrs
6
15%
2
5%
8
20%
21 - 30Yrs 19
47.5%
6
15%
25
62.5%
31-40 Yrs 5
12.5%
2
5%
7
17.5%
TOTAL 30
75%
10
25%
40
100%
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TREATMENT BY POTASSIUM LEVELS
TREATMENT SERUM POTASSIUM IN meq/L TOTAL
1-2 2.1to 3.0
3.1 to 
3.5
3.6to 
4.0 >4
Oral KCL alone - 1845%
9
22.5%
4
10%
1
2.5%
32
80%
Oral KCL+ IV KCL 4
2.5%
2
12.5% - - -
6
15%
Oral 
KCL+acetazolamide
- 2
5%
- - - 25%
TOTAL 4
10%
22
55%
9
22.5%
4
10%
1
2.5%
40
100%
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DISCUSSION
The age at which hypokalemic periodic paralysis presents is usually in 
the second decade18 as per literature.   But in this study,  the commonest  age 
group is in the third decade.  The next is presentation in their second decade and 
less commonly in the Fourth decade .  The disorder is less common after Fourth 
decade.   In  this  study  no  one  has  presented  with  features  of  hypokalemic 
periodic paralysis after fourth decade, even though cases have been reported in 
their  seventh  decade  also  as  evidenced  by  a  cases  report19  published  by 
Decaux O, Poinsingnon Y,  Rosenbaum D, Sternberg B,  Douissiere  Jardel  J, 
Jardel H. 
This variation may be due to the fact that children less than 14 years are 
referred to Institute of Child Health, Chennai and also the Frequency of attacks 
decreases as the age advances, and also most of these patients have  past history 
of similar episodes which they have ignored or treated elsewhere.  This may 
limit analysis of the age adjusted data with literatures. So assessing the past 
history of a similar weakness is very important.
The male gender is commonly affected than  females for every female 
patient approximately three males were affected.  This can be attributed to the 
fact that the penetrance8 is supposed to be mild in females as this is supported 
by study  by Kawamura S , Ikeda Y, Tomita K. Watanabe N, Sekik .
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  Another important factor is that females might have a very mild disease and 
hence many times  the manifestations are not obvious. 
Most of the patients have first degree relative with a similar episodes.  In 
my study around 40% of the  patients have family history21 of similar episodes. 
In a study conducted by Desilva HJ, Senanayake N around 40% of patients had 
family history of hypokalemic periodic paralysis.
As mentioned earlier, these patients can have repeated episodes of flaccid 
weakness.  In  between  attacks,  the  patient  will  be  absolutely  normal.   Even 
though  the  exact  factors  which  determine  the  frequency  of  attacks  are  not 
known  there  can  be  certain  factors  which  can  precipitate  acute  attacks  in 
particular patients.  
The  precipitating  factors  which  have  commonly  been  observed  are  a 
heavy carbohydrate diet followed good sleep.  The less common presentation 
has been that the patient after a strenuous day and a heavy dinner goes to bed. 
on waking up early morning he finds that he is unable to move either his lower 
limbs or both upper and lower limbs .  Hence these  patients should avoid heavy 
meals  and rather should take frequent small meals.  Though it is reported in 
literature, no patient had weakness during or immediately following exercise, in 
our study group.
With regards to clinical presentation many of these patient had presented 
with flaccid quadriparesis / plegia.  Some of the patient had presented with 
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flaccid paraplegia/paresis .  Most of the patient had depressed tendon reflexes 
and  plantar  that  was  not  elicitable.   No patient  had presented  with  sensory 
symptoms bladder or bowel involvement. 
The duration of illness varied with each patient but most  patients had 
recovery time that is between 12 and  24 hours. Only two patients had flaccid 
weakness that lasted  for 48 hours.
Most of the patients had weakness of neck muscles.   But none of the 
patients had difficulty in swallowing, breathing.  Also none of the patient had 
cranial nerve involvement.
The diagnosis of hypokalemic periodic paralysis  is supported by a low 
potassium level during the time of the attacks.  Out of 40 patients about 85% of 
the patient had low serum potassium levels.  It is observed that patients have 
suffered attack of paresis even in low normal range of serum potassium.
In our case study most of the cases had serum potassium level between 2 
to 3 meq / L and some of the patients had levels between 1 to 2 meq /L . 
Electrocardiographic changes26 of hypokalemic periodic paralysis  were 
seen in 80% of the patients.  The common findings were disappearance of T 
waves and prominent  U waves. Some of the patient had  depressed ST segment. 
In   20%  of  patients,  electrocardiogram  were  normal  despite  of  low  serum 
potassium  level.  Hence one should keep in mind that the ECG does not always 
correlate with  serum potassium level.
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In my study there is no correlation between the severity of the attack and 
the level of serum potassium.  Also, there is no correlation between the duration 
of weakness and the initial serum potassium levels.
None of the patient had previous history of surgery.  As there patient are 
at  increased  risk  of  developing  malignant  hyperthermia5,  a  life  threatening 
complication  of  anesthesia,  the  attending  surgeon  and  anesthetist  should  be 
informed  about  this  in  case  of  surgery.  Also  the  patients   were  counseled 
regarding this.  
Some of the other investigations that would be useful are.
1. EMG
2. Muscle biopsy.
As per the study various treatment modalities have been used by different 
physicians.  No single protocol has been followed.  The most frequently  used 
mode  of  treatment  has  been  oral  potassium  chloride  or  a  combination  of 
acetazolamide with potassium chloride.
Six patients has been treated with Intravenous potassium chloride. 
All patients are instructed to take  plenty of  orange  juices and tender coconut 
which is supposed   to contain 70  meq /L of potassium.
Universally the outcome of any type of presentation has been good. 
But it  has taken different time period for complete recovery.  This would be 
due to three factors.
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1. Absence of any particular protocol  for treatment to be followed.
2. The potassium level at the time of presentation
3. The genetic variations.
But it is important to correct the hypokalemia at the earliest or other wise the 
patient can develop.
1. cardiac arrhythmias
2. Respiratory paralysis
3. Muscle  fiber  can  suffer  damage  leading  ultimately  to  progressive 
muscle weakness.
CONCLUSION
49
ON HYPOKALEMIC PERIODIC PARALYSIS
 Incidence ratio  M: F = 3:1
 Commonest age group is in the third decade
 40% have had similar attack in the past
 Flaccid quadriparesis  was the commonest mode of 
presentation.
 About 37% of the patient  had  first degree relative with 
similar attacks
 Most of the patient have had serum potassium level 
between 2 to 3 meq/L
 ECG abnormalities has been observed in 80% of the 
patients most of these patients were treated with oral 
potassium chloride alone 
 Outcome was good in all patients.
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